B-cell Malignancies
📧 Sign up to get email alerts when something new happens for B-cell Malignancies.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies [Phase 1, Phase 2]
This is a clinical trial update for a Phase 1/2 study of BGB-16673 in combination with other agents for relapsed or refractory B-cell lympho…
-
CLINICAL_TRIALS research · 2026-04-15Clinical Trial Update: Phase I Clinical Study to Evaluate SYS6055 Injection in Participants With Relapsed/Refractory B-Cell Malignancies [Phase 1]
A Phase I study to evaluate SYS6055 injection in participants with relapsed/refractory B-cell malignancies is not yet recruiting. The study …
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Expression of CD274 (PD-L1) and CD276 in B-cell Malignancies: A Study by Flowcytometry
A clinical trial update from Assiut University examining expression of PD-L1 (CD274) and CD276 in B-cell malignancies using flow cytometry; …
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies. [Phase 1, Phase 2]
AstraZeneca is conducting a study to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy of AZD5492, a CD20-targeting T cell-e…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies [Phase 1]
This Phase 1 trial update describes evaluating ABBV-101 in adults with B-cell malignancies to assess adverse events, changes in disease acti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies [EARLY_Phase 1]
An exploratory Phase 1 study is evaluating an mRNA therapy targeting CD19 for B-cell malignancies. The trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies [Phase 1, Phase 2]
Phase 1/2 study of SHB-04-CD22 CAR-T therapy targeting CD22 in CD22-expressing B-cell malignancies; the trial is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies [NA]
A clinical study evaluating the safety and efficacy of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies is currently recruiti…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: Exploratory Study on the Treatment of Relapsed and Refractory B-cell Malignant Tumors With WGb-0301 Injection [EARLY_Phase 1]
An early-phase exploratory study of WGb-0301 injection for relapsed and refractory B-cell malignancies, sponsored by Sichuan University, whi…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) [Phase 1]
This Clinical Trial Update describes BaseCAR-01, a Phase 1 study evaluating bispecific CAR T cells in B-cell malignancies, with recruitment …
-
CLINICAL_TRIALS research · 2025-12-16Clinical Trial Update: Zanubrutinib and Acalabrutinib Use and Risk of Atrial Fibrillation in Patients With Chronic B-cell Malignancies
A clinical trial update examining the use of zanubrutinib and acalabrutinib in chronic B-cell malignancies and noting the risk of atrial fib…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) [Phase 2]
A Phase 2 rollover study to provide continued Parsaclisib treatment for participants with B-cell malignancies who previously enrolled in Par…
-
CLINICAL_TRIALS research · 2025-12-03Clinical Trial Update: Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies [Phase 1]
Phase 1 dose-determining study evaluating EXS73565 in participants with relapsed or refractory B-cell malignancies; currently recruiting.
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies [EARLY_Phase 1]
This clinical trial update describes an early-phase study evaluating the safety and potential efficacy of the investigational drug ZZSW-01 i…
-
CLINICAL_TRIALS research · 2025-11-19Clinical Trial Update: UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies [Phase 1]
Ubix Therapeutics is recruiting for a Phase 1 study of UBX-303061 to treat relapsed/refractory B-cell malignancies. The document notes ongoi…
-
CLINICAL_TRIALS research · 2025-10-21Clinical Trial Update: Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies [Phase 3]
A Phase 3 long-term extension study of zanubrutinib (BGB-3111) regimens is being conducted in participants with B-cell malignancies; the tri…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies [Phase 1, Phase 2]
A Phase I/II multi-center trial evaluating 4SCAR19 CAR-T cells for relapsed or refractory B-cell malignancies; the study is currently recrui…
-
CLINICAL_TRIALS research · 2025-09-08Clinical Trial Update: Combination CAR-T Cell Therapy Targeting Hematological Malignancies [Phase 1, Phase 2]
A Phase 1/2 clinical trial update for a combination CAR-T cell therapy targeting hematological malignancies, currently recruiting for B-cell…
-
CLINICAL_TRIALS research · 2025-07-15Clinical Trial Update: JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies [NA]
A clinical trial update indicates JY231 injection is being studied for relapsed/refractory B-cell malignancies and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-05-16Clinical Trial Update: UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies. [EARLY_Phase 1]
UTAA09 Injection is being evaluated in an early Phase 1 trial for CD19-positive relapsed or refractory B-cell malignancies, with patient rec…
-
CLINICAL_TRIALS research · 2025-05-14Clinical Trial Update: Evaluation of SYS6005 in Patients With Advanced Malignant Tumor [Phase 1]
Phase 1 study evaluating SYS6005 in adults with advanced malignant tumors, including B-cell malignancies and solid tumors. The trial is curr…
-
CLINICAL_TRIALS research · 2025-03-27Clinical Trial Update: Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
This clinical trial update evaluates the prevalence and risk factors of persistent COVID-19 in immunocompromised patients, focusing on those…